False positive tumor markers: elevation in patients with breast cancer on FAC-type chemotherapy and correlation with the development of hand-foot syndrome.
Breast cancer patients on dose-intensive chemotherapy often have elevated tumor markers during the course of treatment. Our objective was to estimate the incidence of a "false positive" tumor marker screen and to determine whether hand-foot epithelial damage was correlated. Data from 53 patients with high risk primary breast cancer who had undergone adjuvant or neoadjuvant 5FU-containing chemotherapy (FAC or FAC plus G-CSF) for 3 to 12 months were reviewed. The relationship between tumor marker elevation and disease recurrence, regimen intensity, and the occurrence of hand-foot syndrome was examined. Thirty-three of the 53 patients had elevated tumor markers in the absence of recurrent disease. The false positive rate was higher in patients who underwent FAC plus G-CSF chemotherapy than in patients who underwent FAC chemotherapy (92% vs 55%, p = .01). A false positive marker screen was associated with the occurrence of hand-foot syndrome even when the effect of regimen was accounted for by stratification (p = .01). Tumor marker screening of breast cancer patients on this type of adjuvant chemotherapy has poor specificity for recurrent malignancy. These data suggest tumor marker elevation may be an indicator of epithelial toxicity during chemotherapy, manifested clinically as hand-foot syndrome.
Tyshler
L B
LB
University of Washington Cancer Center, Seattle, USA.
Longton
G M
GM
Ellis
G K
GK
Livingston
R B
RB
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D005189:False Positive Reactions; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D005528:Foot; D006225:Hand; D006801:Humans; D018396:Mucin-1 / Q000032:analysis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C090797:CA 27-29 antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil